Market research projects the longevity biotech sector will exceed $31 billion by 2030 at an 8% compound annual growth rate, accounting for roughly 78% of the broader longevity and anti-senescence therapy market. Preventive health programs are forecast to dominate at 41% of service revenue, with biological age testing contributing approximately $5 billion. Capital is concentrating on measurement and prevention rather than late-stage intervention, while the field remains highly fragmented.
Key Points
- Longevity biotech projected above $31 billion by 2030
- Preventive programs lead at 41% of service revenue
- Biological age testing forecast to add $5 billion
Longevity Analysis
Commercial momentum is shifting toward measurement and prevention rather than treatment of established disease, with biological age testing emerging as a distinct revenue category. That shift mirrors what practitioners already observe clinically: accurate interpretation of what the body is signalling — inflammatory load, metabolic reserve, repair capacity — determines whether any subsequent intervention is appropriate. Cellular reprogramming and senolytic approaches targeting tissue renewal remain early-stage, and the extreme fragmentation of the sector, with the top ten firms holding roughly 0.3% of 2025 revenue, indicates that no dominant clinical standard has yet emerged.
Original published by LT Wire.